Treatment of acute migraine with sumatriptan--response in 40 consecutive patients.
Forty consecutive headache patients self-administered sumatriptan for migraine, diagnosed by the criteria of the International Headache Society (IHS). Eighty percent reported excellent response. Thirty-three percent had recurrence of headache within four to twelve hours, while 67% had no recurrence. Fifty-five percent of the patients reported mild side effects, but only 8% stopped therapy because of adverse reactions. No serious cardiovascular events occurred. Recommendations for safe use of sumatriptan are suggested.
Blumenthal
H J
HJ
Department of Internal Medicine, University of Oklahoma College of Medicine-Tulsa 74129-1077, USA.
Weisz
M A
MA
Burk
S
S
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D012646:Self Administration; D012720:Severity of Illness Index; D018170:Sumatriptan / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D018170:Sumatriptan